Amphastar Pharmaceuticals, Inc.AMPHNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-44.09%
↓ 120% below average
Average (39q)
217.24%
Historical baseline
Range
High:5405.41%
Low:-593.60%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -44.09% |
| Q2 2025 | 22.72% |
| Q1 2025 | -33.40% |
| Q4 2024 | -6.10% |
| Q3 2024 | 6.54% |
| Q2 2024 | -12.11% |
| Q1 2024 | 19.38% |
| Q4 2023 | -26.52% |
| Q3 2023 | 88.42% |
| Q2 2023 | 0.35% |
| Q1 2023 | -23.24% |
| Q4 2022 | 113.64% |
| Q3 2022 | -8.49% |
| Q2 2022 | -28.48% |
| Q1 2022 | 22.74% |
| Q4 2021 | -33.13% |
| Q3 2021 | 280.43% |
| Q2 2021 | 54.08% |
| Q1 2021 | 180.36% |
| Q4 2020 | -260.07% |
| Q3 2020 | 2141.15% |
| Q2 2020 | -104.86% |
| Q1 2020 | 484.89% |
| Q4 2019 | -178.32% |
| Q3 2019 | -97.26% |
| Q2 2019 | 5405.41% |
| Q1 2019 | -53.51% |
| Q4 2018 | -21.85% |
| Q3 2018 | 185.63% |
| Q2 2018 | 61.50% |
| Q1 2018 | -593.60% |
| Q4 2017 | 738.86% |
| Q3 2017 | -91.13% |
| Q2 2017 | 120.83% |
| Q1 2017 | 132.57% |
| Q4 2016 | -170.49% |
| Q3 2016 | -43.58% |
| Q2 2016 | 177.02% |
| Q1 2016 | -66.96% |
| Q4 2015 | 350.43% |